NCT07103083招募中不适用
A Randomized, Crossover, Controlled Trial Investigating the Effects of Different Cranberry-Based Beverages on Postprandial Glucose, Insulin, and GLP-1
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Blood glucose iAUC - 2 hours
研究概览
简要总结
The goal of this clinical trial is to determine postprandial responses to fruit juices.
详细描述
Fruit juice is commonly consumed as a part of a balanced diet because of hydration, flavor, and nutrient content . Dietary Guidelines for Americans 2020-2025 recognizes 100% fruit juice as a nutrient-dense beverage that can contribute to fruit and nutrient intake . Liquid form of juices may lead to faster absorption and hormonal responses . Measuring these acute metabolic responses can help clarify the role of fruit juice in dietary patterns and metabolic health .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •≥18 to ≤45 years of age at Visit
- •BMI ≥18.5 and <30.0 kg/m2 at Visit
- •Fasting capillary glucose ≤110 mg/dL at Visit
- •Willing to avoid consuming high-polyphenol containing foods for 48 hours prior to each test visit.
- •Willing to abstain from alcohol consumption for 24 hours prior to each study visit.
- •Non-user of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of Visit 1, with no plans to begin use during the study period.
- •Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including Cannabidiol (CBD)/Tetrahydrocannabinol (THC) products, and willing to abstain from use throughout the study period (topical creams/lotions are allowed).
- •Willing to maintain habitual physical activity level throughout the duration of the study.
- •Willing to maintain habitual dietary pattern throughout the duration of the study, including stable intake of current vitamins, minerals, supplements and medications not interfering with study outcomes.
- •Score of 7 to 10 on the Vein Access Scale at Visit
- •No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history.
- •Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.
排除标准
- •History or presence of clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, gastrointestinal, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Clinical Investigator.
- •Uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the blood pressure measured at Visit 1 (Section 9.1.1).
- •Unstable use (initiation or change in dose) within 30 days of Visit 1 of antihypertensive medications.
- •Unstable use (initiation or change in dose) within 30 days of Visit 1 of thyroid hormone replacement medications.
- •Use of medications or supplements that may influence carbohydrate metabolism within 30 days of Visit
- •Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian) at the discretion of the Clinical Investigator.
- •Weight loss or gain >4.5 kg in the 60 days prior to Visit
- •Currently, or planning to be, on a weight loss regimen during the study.
- •Use of weight loss medication within 90 days of Visit
- •History of gastrointestinal surgery for weight reducing purposes.
- •History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
- •Known allergy or sensitivity to any ingredients or potential allergens contained in the study beverages.
- •History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
- •History of any major trauma or major surgical event within 60 days of Visit
- •Blood donation >450 mL within 60 days of Visit 2 or plans to donate blood or plasma during the study period.
- •Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use (initiation or change in dose) within 30 days of Visit 1) of sex hormones for contraception.
- •Recent history of (within 12 months of screening; Visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- •Exposed to any non-registered drug product within 30 days prior to Visit
- •Any condition the Clinical Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
结局指标
主要结局
Blood glucose iAUC - 2 hours
时间窗: 2 hours
Glucose incremental area under the curve (iAUC) from pre-product consumption to 120 min
次要结局
- Blood glucose maximal concentration(2 hours)
- Blood glucose time to max concentration(2 hours)
- Blood glucose change(2 hours)
- Blood insulin iAUC(2 hours)
- Blood insulin time to max concentration(2 hours)
- GLP-1 iAUC(2 hours)
- Blood insulin maximal concentration(2 hours)
- Blood insulin change(2 hours)
- GLP-1 Maximal Concentration(2 hours)
- GLP-1 Time to Max Concentration(2 hours)
- GLP-1 Change(2 hours)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test FiberHealthyNCT03239288Cargill22
已完成
不适用
The Impact of Fruit Juice, Fruit Juice With Pomace, or Whole Fruit on Glycemic ResponseGlycemic ResponseNCT04369716PepsiCo Global R&D18
已完成
不适用
Effect of Snacks on Appetite ControlHealthy CanadiansAppetite ControlNCT01806688St. Boniface Hospital46
已完成
不适用
Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human MicrobiomeGut MicrobiomeNCT03058575Access Business Group30
终止
不适用
Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.Gestational Diabetes Mellitus in PregnancyNCT02225951Danone Asia Pacific Holdings Pte, Ltd.3